¾Æ½ºÆä¸£±æ·ç½ºÁõ Ä¡·á ½ÃÀå : À¯Çü, ¾àÁ¦ Ŭ·¡½º, ¾àÁ¦ ÇüÅÂ, À¯Åë ä³Îº° - ¼¼°è ¿¹Ãø(2024-2032³â)
Aspergillosis Treatment Market - By Type (Acute, Chronic Aspergillosis), Drug Class (Antifungal Drugs [Azoles, Echinocandins, Polyenes], Corticosteroids [Prednisolone, Prednisone]), Drug Form, Distribution Channel - Global Forecast (2024 - 2032)
»óǰÄÚµå : 1535851
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 231 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 6,882,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,585,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 11,849,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ¾Æ½ºÆä¸£±æ·ç½ºÁõ Ä¡·á ½ÃÀå ±Ô¸ð´Â È­Çпä¹ý, Àå±â À̽Ä, HIV/AIDS ȯÀÚ µî ¸é¿ª ºÎÀüÀÚÀÇ ¾Æ½ºÆä¸£±æ·ç½ºÁõ °¨¿°ÀÇ Áõ°¡¿¡ ÀÇÇØ ÃËÁøµÇ¸ç, 2024-2032³â¿¡ CAGR 4.3%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. CDC¿¡ µû¸£¸é Àå±âÀÌ½Ä È¯ÀÚ Áß ¾à 1-2%°¡ ¾Æ½ºÆä¸£±æ·ç½ºÁõ¿¡ °É¸³´Ï´Ù. -2%°¡ ¾Æ½ºÆä¸£±æ·ç½ºÁõÀ» ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ¶ÇÇÑ Ãµ½Ä°ú COPD¿Í °°Àº È£Èí±â ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, °¢°¢ 2,500¸¸ ¸í ÀÌ»ó, 1,600¸¸ ¸í ÀÌ»óÀÇ ¹Ì±¹ÀÎÀÌ ¾Î°í ÀÖ½À´Ï´Ù. °í·ÉÈ­ »çȸ´Â ¸é¿ª·Â ÀúÇÏ·Î ÀÎÇØ °¨¿°¿¡ Ãë¾àÇØÁ® ¾Æ½ºÆä¸£±æ·ç½ºÁõ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

»õ·Î¿î Ç×Áø±ÕÁ¦ÀÇ °³¹ß°ú Áø´Ü ±â¼úÀÇ Çâ»óÀ¸·Î Ä¡·áÀÇ È¿°ú¿Í Á¤È®¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. Áø±Õ °¨¿°Áõ ¿¬±¸¿¡ ´ëÇÑ Àνİú ÀÚ±ÝÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´õ ³ªÀº Ä¡·á ÇÁ·ÎÅäÄݰú ÀÇ·á ÀÎÇÁ¶ó°¡ °­È­µÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï ±¹°¡¿¡¼­ÀÇ ÀÇ·á ÅõÀÚ È®´ë´Â ½ÃÀåÀ» ´õ¿í °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÷´Ü Ä¡·á¹ý¿¡ ´ëÇÑ Æø³ÐÀº Á¢±Ù°ú ȯÀÚ °á°ú °³¼±À¸·Î À̾îÁú °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

ºÎ½ÅÇÇÁú½ºÅ×·ÎÀÌµå ¾àÁ¦ Ŭ·¡½º ºÎ¹®Àº °¨¿°¿¡ µû¸¥ ¿°Áõ ¹ÝÀÀ °ü¸®¿¡ È¿°úÀûÀ̱⠶§¹®¿¡ 2032³â±îÁö Å« °ßÀηÂÀ» È®º¸ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇÁ·¹µå´Ï¼Õ ¹× ¸ÞÆ¿ÇÁ·¹µå´Ï¼Ö·Ð°ú °°Àº ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵å´Â ¾Ë·¹¸£±â¼º ±â°üÁöÆó ¾Æ½ºÆä¸£±æ·ç½ºÁõ(ABPA) ¹× ¸¸¼º Æó ¾Æ½ºÆä¸£±æ·ç½ºÁõ(CPA) ȯÀÚÀÇ ¿°Áõ ¹× ¸é¿ª¹ÝÀÀÀ» ¾ïÁ¦ÇÏ´Â µ¥ ÀϹÝÀûÀ¸·Î »ç¿ëµË´Ï´Ù. ÀÌ ¾à¹°Àº õ¸íÀ½, È£Èí°ï¶õ, ÈäºÎ ¾Ð¹Ú°¨ µîÀÇ Áõ»óÀ» ¿ÏÈ­½ÃÄÑ È¯ÀÚ¿¡°Ô Å« ¾Èµµ°¨À» ÁÝ´Ï´Ù. È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ¾Æ½ºÆä¸£±æ·ç½ºÁõ ¹ßº´·ü Áõ°¡´Â ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵忡 ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

ÁÖ»çÁ¦ ºÎ¹®Àº ¾à¹°Àü´Þ ¹× È¿´É Ãø¸é¿¡¼­ À¯¸®ÇϹǷΠ2032³â±îÁö ÁÖ¸ñÇÒ ¸¸ÇÑ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÁÖ»çÁ¦´Â °í¿ë·®ÀÇ ¾à¹°À» Ç÷·ù·Î Á÷Á¢ Àü´ÞÇÒ ¼ö ÀÖÀ¸¹Ç·Î ÁßÁõ ¾Æ½ºÆä¸£±æ·ç½ºÁõ°ú Àü½Å ¾Æ½ºÆä¸£±æ·ç½ºÁõÀ» º¸´Ù ½Å¼ÓÇϰí È¿°úÀûÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Åõ¿© °æ·Î´Â ÁßÁõ Áø±Õ °¨¿°Áõ ȯÀÚ³ª À§Àå Àå¾Ö³ª Èí¼ö Àå¾Ö·Î ÀÎÇØ °æ±¸¿ë ¾à¹°À» º¹¿ëÇÒ ¼ö ¾ø´Â ȯÀÚ¿¡°Ô ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ½Å¼ÓÇϰí È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ÁÖ»çÁ¦ Á¦ÇüÀÇ ¹ßÀü°ú ÇÔ²² ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹ÌÀÇ ¾Æ½ºÆä¸£±æ·ç½ºÁõ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â Áø±Õ °¨¿°ÁõÀÇ ³ôÀº À¯º´·ü, ÷´ÜÈ­µÈ ÀÇ·á ÀÎÇÁ¶ó, dzºÎÇÑ ¿¬±¸ ÅõÀÚ·Î ÀÎÇØ 2032³â±îÁö ºü¸¥ ¼Óµµ·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀÇ Àß ±¸ÃàµÈ ÀÇ·á ½Ã½ºÅÛ°ú ¿ì¼öÇÑ ÀÇÇÐ ¿¬±¸ ¿ª·®Àº Çõ½ÅÀûÀÎ Ä¡·á ¿É¼ÇÀÇ °³¹ß°ú äÅÃÀ» ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ ¸¸¼º È£Èí±â Áúȯ°ú ¸é¿ª °áÇÌ ÁúȯÀÇ ¹ßº´·üÀÌ Áõ°¡Çϸ鼭 È¿°úÀûÀÎ ¾Æ½ºÆÛ±æ·ç½ºÁõ Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¼º°ú Çâ»óÀ» À§ÇÑ Á¤ºÎÀÇ ±¸»ó°ú ÀçÁ¤ Áö¿øÀº ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : À¯Çüº°(2021-2032³â)

Á¦6Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ¾àÁ¦ Ŭ·¡½ºº°(2021-2032³â)

Á¦7Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Á¦Çüº°(2021-2032³â)

Á¦8Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : À¯Åë ä³Îº°(2021-2032³â)

Á¦9Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áö¿ªº°(2021-2032³â)

Á¦10Àå ±â¾÷ °³¿ä

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Aspergillosis treatment market is anticipated to record 4.3% CAGR over 2024-2032, driven by a rise in Aspergillosis infections among immunocompromised individuals, such as those undergoing chemotherapy, organ transplants, or living with HIV/AIDS. According to the CDC, about 1-2% of organ transplant recipients develop Aspergillosis. Additionally, there is increasing prevalence of respiratory conditions like asthma and COPD, which affect over 25 million and 16 million Americans respectively. The aging population, more susceptible to infections due to weakened immune systems, further boosts demand for Aspergillosis treatments.

The development of new antifungal agents and improved diagnostic techniques has enhanced treatment efficacy and accuracy. Increased awareness and funding for fungal infection research have led to better treatment protocols and stronger healthcare infrastructure. Growing healthcare investments, particularly in emerging economies, are expected to further drive the market, ensuring wider access to advanced treatments and improving patient outcomes.

The overall Aspergillosis treatment industry is classified based on type, drug class, drug form, distribution channel, and region.

The corticosteroids drug class segment is poised to gain substantial traction through 2032 due to its effectiveness in managing inflammatory responses associated with the infection. Corticosteroids, such as prednisone and methylprednisolone, are commonly used to reduce inflammation and immune responses in patients with allergic bronchopulmonary aspergillosis (ABPA) and chronic pulmonary aspergillosis (CPA). These drugs help alleviate symptoms such as wheezing, shortness of breath, and chest tightness, providing significant relief to patients. The increasing prevalence of respiratory conditions and the rising incidence of Aspergillosis are driving the demand for corticosteroids.

The injections segment will hold a notable market share by 2032, owing to the advantages it offers in terms of drug delivery and efficacy. Injectable formulations are preferred for their ability to deliver high doses of medication directly into the bloodstream, ensuring faster and more effective treatment of severe or systemic Aspergillosis infections. This route of administration is crucial for patients with severe fungal infections or those who cannot tolerate oral medications due to gastrointestinal issues or absorption problems. The growing emphasis on rapid and effective treatment options, coupled with advancements in injectable drug formulations, is driving the segment growth.

North American Aspergillosis treatment market size will expand at a rapid pace through 2032, driven by high prevalence rate of fungal infections, advanced healthcare infrastructure, and substantial research investments. The region's well-established healthcare systems and significant medical research capabilities facilitate the development and adoption of innovative treatment options. Additionally, the rising incidence of chronic respiratory diseases and immunocompromised conditions contributes to the increased demand for effective Aspergillosis therapies. Government initiatives and funding aimed at improving healthcare outcomes further bolster market growth across the region.

Table of Contents

Chapter 1 Methodology & Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2023

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

Chapter 7 Market Estimates and Forecast, By Drug Form, 2021 - 2032 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

Chapter 10 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â